Granahan Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Granahan Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-749,740	Closed	-$3.37M	–	193
2021 Q4	$3.37M	Sell	749,740 -71,914	-9%	-$341K	0.07%	168
2021 Q3	$3.99M	Sell	821,654 -12,606	-2%	-$69.5K	0.08%	164
2021 Q2	$5.69M	Sell	834,260 -23,318	-3%	-$189K	0.11%	148
2021 Q1	$6.05M	Buy	857,578 +281,456	+49%	+$2.03M	0.13%	131
2020 Q4	$3.61M	Sell	576,122 -112,124	-16%	-$660K	0.08%	148
2020 Q3	$3.72M	Buy	688,246 +5,143	+0.8%	+$25.5K	0.13%	124
2020 Q2	$3.57M	Sell	683,103 -19,629	-3%	-$87.2K	0.13%	121
2020 Q1	$2.21M	Sell	702,732 -9,363	-1%	-$34.5K	0.12%	124
2019 Q4	$2.87M	Buy	712,095 +534,222	+300%	+$1.85M	0.13%	124
2019 Q3	$768K	Buy	177,873 +11,361	+7%	+$45.4K	0.04%	164
2019 Q2	$664K	Sell	166,512 -2,263	-1%	-$10.8K	0.03%	171
2019 Q1	$905K	Sell	168,775 -11,735	-7%	-$75.8K	0.05%	174
2018 Q4	$926K	Sell	180,510 -3,105	-2%	-$23.6K	0.07%	169
2018 Q3	$1.78M	Buy	183,615 +7,077	+4%	+$71.4K	0.1%	161
2018 Q2	$1.8M	Buy	+176,538	New	+$2M	0.11%	169
2017 Q3	–	Sell	-51,238	Closed	-$1.24M	–	239
2017 Q2	$1.24M	Sell	51,238 -201,962	-80%	-$4.46M	0.11%	150
2017 Q1	$4.87M	Sell	253,200 -202,030	-44%	-$3.18M	0.49%	74
2016 Q4	$7.01M	Buy	455,230 +32,000	+8%	+$415K	0.24%	133
2016 Q3	$5.51M	Buy	423,230 +72,030	+21%	+$955K	0.18%	147
2016 Q2	$4.88M	Buy	351,200 +29,930	+9%	+$441K	0.18%	153
2016 Q1	$4.87M	Sell	321,270 -7,749	-2%	-$119K	0.18%	156
2015 Q4	$6.24M	Sell	329,019 -11,269	-3%	-$215K	0.21%	143
2015 Q3	$6.46M	Buy	340,288 +198,912	+141%	+$4.96M	0.2%	158
2015 Q2	$3.64M	Buy	141,376 +65,890	+87%	+$1.87M	0.1%	194
2015 Q1	$2.36M	Buy	+75,486	New	+$2.17M	0.07%	208

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Granahan Investment Management's PRTK Position: Q1 2022 in Review

Granahan Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 749,740 shares — an estimated $3.37M sold.

Granahan Investment Management first reported a position in PRTK in Q1 2015 and held it in 25 quarters. The position peaked at $7.01M in Q4 2016. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Granahan Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Granahan Investment Management sold 749,740 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $3.37M.
Granahan Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2015 and held it in 25 quarters.
Granahan Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $7.01M in Q4 2016.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Granahan Investment Management's 13F filing for Q1 2022, filed 16 May 2022.